ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer - Episode 10

DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival

, , ,

In a detailed analysis, key opinion leaders (KOLs) review the results of the DELLphi-301 Phase 2 clinical trial, assessing the efficacy of platinum-based chemotherapy in the treatment of small cell lung cancer (SCLC) and its impact on overall survival outcomes for patients enrolled in the study.

EP. 1: Optimizing First-Line Therapy for Limited-Stage Small Cell Lung Cancer
EP. 2: ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC
EP. 3: cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC
EP. 4: Examining 3-Year Update Data from the CASPIAN Trial
EP. 5: Predictors of Immunotherapy Response in Limited and Extensive SCLC
EP. 6: Overcoming Immunotherapy Resistance in Small Cell Lung Cancer
EP. 7: Examining the use of PD-L1 and tTMB in the CASPIAN Trial
EP. 8: Redefining SCLC: Molecular Subtypes and Blood Biomarkers Guide Therapy
EP. 9: Navigating Later-Line Therapy Sequencing in LS-SCLC Progression
Now Viewing
EP. 10: DELLphi-301: Platinum Chemotherapy Efficacy in SCLC Survival
EP. 11: Reviewing Ideate-Lung02: Durable Responses in Advanced SCLC
EP. 12: Examining Key Data from DAREON-8
EP. 13: Closing Thoughts and Key Takeaways on Small Cell Lung Cancer

Video content above is prompted by the following questions:

  • DELLphi-301 Phase 2 Clinical Trial of Tarlatamab
    • Please share your insights on the importance of ORR and DoR in patients with ES-SCLC who have relapsed or who are refractory to platinum-based chemotherapy.
    • At the community practice level, does 90 days continue to mark platinum sensitivity status among patients with ES SCLC?
    • What other factors contribute to the definition of treatment resistance in this patient subgroup?
    • How clinically meaningful is a median OS of 14 months and a DoR of between 6 and 9 months in patients with relapsed or refractory ES SCLC?
    • How do you weigh the risk-benefit ratio of treatment with tarlatamab in relapsed or refractory ES SCLC?
    • To what degree might a Black Box warning on risk of CRS and ICANS impact ready adoption of this new therapy by community oncologists for their patients with progressive ES SCLC?
    • Given that no fatal CRS or ICANS events were reported with the 10 mg dose and only one dose interruption was reported in Part 1 and 2 of the published Phase II study report, what is the potential to reduce patient monitoring time between bimonthly infusions of tarlatamab?